Profile | GDS2987 / GI_13376676-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 295.8 | 87 |
GSM215244 | HMVEC_vehicle_rep2 | 448.2 | 89 |
GSM215253 | HMVEC_vehicle_rep3 | 332.7 | 87 |
GSM215254 | HMVEC_atorvastatin_rep1 | 407.4 | 89 |
GSM215282 | HMVEC_atorvastatin_rep3 | 523 | 90 |
GSM215344 | HMVEC_atorvastatin_rep2 | 581.7 | 91 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 336.7 | 87 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 416.1 | 88 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 459.8 | 89 |
GSM215294 | HMVEC_SLx2119_rep1 | 560.7 | 92 |
GSM215295 | HMVEC_SLx2119_rep2 | 578.8 | 91 |
GSM215296 | HMVEC_SLx2119_rep3 | 521.1 | 90 |
GSM215297 | PASMC_vehicle_rep1 | 522.9 | 89 |
GSM215298 | PASMC_vehicle_rep2 | 457.1 | 88 |
GSM215310 | PASMC_vehicle_rep3 | 357.3 | 86 |
GSM215311 | PASMC_atorvastatin_rep1 | 131.7 | 77 |
GSM215312 | PASMC_atorvastatin_rep2 | 145.1 | 78 |
GSM215313 | PASMC_atorvastatin_rep3 | 160.5 | 78 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 470.8 | 88 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 440.8 | 88 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 408.6 | 87 |
GSM215327 | PASMC_SLx2119_rep1 | 268.7 | 84 |
GSM215328 | PASMC_SLx2119_rep2 | 338.5 | 86 |
GSM215329 | PASMC_SLx2119_rep3 | 271.8 | 84 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 2.2 | 6 |
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 3.9 | 11 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 12.5 | 39 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 10.5 | 32 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 22.8 | 52 |
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 37.5 | 63 |